From the latest 4D. OBJ believes any potential partner will only...

From the latest 4D.

OBJ believes any potential partner will only engage if there is a strong focus on getting the BodyCare product to the US market, which would require approval from the US Food and Drug Administration (FDA).  In the case of BodyCare, there is potential it could follow either an OTC or an Rx pathway depending on the type of pain and duration of treatment.  This is likely to mean that a new drug application (NDA) for both paths must be filed.

Since the completion of the IBU study, OBJ engaged in discussions with potential partner companies as well as exploring a ‘go it alone’ strategy to develop BodyCare as a new, stand-alone brand.

From previous 4D

A Major US based licensee waits in the wings for the results of current clinical trial for ibuprofen delivery a Curtin University. Expected to be finished during the March Quarter. With A UK clinical trial to be conducted on Bodyguard during the March Quarter.​

So what's happened with the US based licensee that was waiting in the wings and who I believe helped with the design of the Curtain Study?
Why the need to explore a go it alone scenario when the trial results were deemed to be so positive?

What's happened with the UK clinical Study for Bodyguard slated for March?
Apparently this has become a consumer exposure/proof of concept study.
Why can't investors get access to raw trial data?